Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
Apellis Pharmaceuticals (Nasdaq: APLS) announced it will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET.
Investors can pre-register for the call, and a live audio webcast with accompanying slides will be available through the company's website. The webcast replay will be accessible for 90 days after the event.
Apellis Pharmaceuticals (Nasdaq: APLS) ha annunciato che terrà una conference call e una diretta webcast per discutere i risultati finanziari del secondo trimestre 2025 il giovedì 31 luglio 2025 alle 8:30 ET.
Gli investitori possono preregistrarsi per la chiamata; la diretta audio con le slide sarà disponibile sul sito web dell'azienda. La registrazione della webcast sarà accessibile per 90 giorni dopo l'evento.
Apellis Pharmaceuticals (Nasdaq: APLS) anunció que realizará una llamada de conferencia y una transmisión en vivo para discutir los resultados financieros del segundo trimestre de 2025 el jueves 31 de julio de 2025 a las 8:30 a.m. ET.
Los inversionistas pueden preregistrarse para la llamada, y una transmisión en vivo con audio y diapositivas estará disponible en el sitio web de la compañía. La repetición de la transmisión estará disponible durante 90 días después del evento.
Apellis Pharmaceuticals (나스닥: APLS)는 2025년 2분기 재무 실적에 대해 논의하기 위해 2025년 7월 31일 목요일 오전 8시 30분(동부시간)에 컨퍼런스 콜과 웹캐스트를 개최한다고 발표했습니다.
투자자들은 콜 사전 등록이 가능하며, 회사 웹사이트를 통해 오디오 웹캐스트와 슬라이드가 제공됩니다. 웹캐스트 녹화는 행사 후 90일간 다시 보기 가능합니다.
Apellis Pharmaceuticals (Nasdaq : APLS) a annoncé qu'elle tiendra une conférence téléphonique et une diffusion en direct pour discuter des résultats financiers du deuxième trimestre 2025 le jeudi 31 juillet 2025 à 8h30 ET.
Les investisseurs peuvent se préinscrire à l'appel, et une diffusion audio en direct accompagnée de diapositives sera disponible sur le site web de la société. La rediffusion du webcast sera accessible pendant 90 jours après l'événement.
Apellis Pharmaceuticals (Nasdaq: APLS) gab bekannt, dass es am Donnerstag, den 31. Juli 2025, um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast zur Besprechung der Finanzergebnisse des zweiten Quartals 2025 abhalten wird.
Investoren können sich vorab für den Anruf registrieren, und ein Live-Audio-Webcast mit begleitenden Folien wird über die Website des Unternehmens verfügbar sein. Die Aufzeichnung des Webcasts wird 90 Tage nach der Veranstaltung abrufbar sein.
- None.
- None.
WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET.
To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Neil Carnahan
neil.carnahan@apellis.com
617.977.5703
FAQ
When is Apellis Pharmaceuticals (APLS) Q2 2025 earnings call?
How can investors access the Apellis Pharmaceuticals Q2 2025 earnings call?
How long will the Apellis Q2 2025 earnings call replay be available?
What does Apellis Pharmaceuticals (APLS) specialize in?
